Literature DB >> 30370094

Review of nintedanib plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma: phase II results from the randomized, placebo-controlled LUME-Meso trial.

Pyng Lee1.   

Abstract

Entities:  

Year:  2018        PMID： 30370094      PMCID： PMC6186601          DOI： 10.21037/jtd.2018.07.105

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  20 in total

Review 1.  Second line therapy in malignant pleural mesothelioma: A systematic review.

Authors:  Wieneke A Buikhuisen; Birgitta I Hiddinga; Paul Baas; Jan P van Meerbeeck
Journal:  Lung Cancer       Date:  2015-06-23       Impact factor: 5.705

Review 2.  Five years update on relationships between malignant pleural mesothelioma and exposure to asbestos and other elongated mineral particles.

Authors:  Pascal Andujar; Aude Lacourt; Patrick Brochard; Jean-Claude Pairon; Marie-Claude Jaurand; Didier Jean
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2016       Impact factor: 6.393

3.  Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.

Authors:  Gérard Zalcman; Julien Mazieres; Jacques Margery; Laurent Greillier; Clarisse Audigier-Valette; Denis Moro-Sibilot; Olivier Molinier; Romain Corre; Isabelle Monnet; Valérie Gounant; Frédéric Rivière; Henri Janicot; Radj Gervais; Chrystèle Locher; Bernard Milleron; Quan Tran; Marie-Paule Lebitasy; Franck Morin; Christian Creveuil; Jean-Jacques Parienti; Arnaud Scherpereel
Journal:  Lancet       Date:  2015-12-21       Impact factor: 79.321

4.  Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.

Authors:  Jan P van Meerbeeck; Rabab Gaafar; Christian Manegold; Rob J Van Klaveren; Eric A Van Marck; Mark Vincent; Catherine Legrand; Andrew Bottomley; Channa Debruyne; Giuseppe Giaccone
Journal:  J Clin Oncol       Date:  2005-10-01       Impact factor: 44.544

5.  Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.

Authors:  Wieneke A Buikhuisen; Jacobus A Burgers; Andrew D Vincent; Catharina M Korse; Rob J van Klaveren; Franz M N H Schramel; Nick Pavlakis; Anna K Nowak; Frank L J Custers; J Hugo Schouwink; Steven J M Gans; Harry J M Groen; Wim F M Strankinga; Paul Baas
Journal:  Lancet Oncol       Date:  2013-04-12       Impact factor: 41.316

6.  Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003-2008.

Authors:  S Jane Henley; Theodore C Larson; Manxia Wu; Vinicius C S Antao; Mary Lewis; Germania A Pinheiro; Christie Eheman
Journal:  Int J Occup Environ Health       Date:  2013 Jan-Mar

7.  Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma.

Authors:  A Scherpereel; P Astoul; P Baas; T Berghmans; H Clayson; P de Vuyst; H Dienemann; F Galateau-Salle; C Hennequin; G Hillerdal; C Le Péchoux; L Mutti; J-C Pairon; R Stahel; P van Houtte; J van Meerbeeck; D Waller; W Weder
Journal:  Eur Respir J       Date:  2009-08-28       Impact factor: 16.671

Review 8.  Radiotherapy for the treatment of malignant pleural mesothelioma.

Authors:  Marc de Perrot; Licun Wu; Matthew Wu; B C John Cho
Journal:  Lancet Oncol       Date:  2017-09       Impact factor: 41.316

9.  Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Hedy L Kindler; Nofisat Ismaila; Samuel G Armato; Raphael Bueno; Mary Hesdorffer; Thierry Jahan; Clyde Michael Jones; Markku Miettinen; Harvey Pass; Andreas Rimner; Valerie Rusch; Daniel Sterman; Anish Thomas; Raffit Hassan
Journal:  J Clin Oncol       Date:  2018-01-18       Impact factor: 44.544

10.  The European mesothelioma epidemic.

Authors:  J Peto; A Decarli; C La Vecchia; F Levi; E Negri
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640
View more
  1 in total

1.  Gender differences in molecular-guided therapy recommendations for metastatic malignant mesothelioma.

Authors:  Hossein Taghizadeh; Sabine Zöchbauer-Müller; Robert M Mader; Leonhard Müllauer; Thomas Klikovits; Thomas Bachleitner-Hofmann; Mir A Hoda; Gerald W Prager
Journal:  Thorac Cancer       Date:  2020-05-21       Impact factor: 3.500
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.